Aclidinium Bromide Gains Reluctant Advisory Committee Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
Pulmonary-Allergy Drugs Advisory Committee members say post-marketing study is necessary, and Forest has already made a preliminary proposal.
You may also be interested in...
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.
US FDA's CDER Creates Quantitative Medicine Center Of Excellence; Job Includes AI Oversight
The group will coordinate quantitative medicine issues throughout the FDA's Center for Drug Evaluation and Research to help streamline drug development.